Caprion Biosciences Offers Mass Cytometry CRO Services to Advance Biomarker Discovery and Immune Monitoring
8 janvier 2019
SOUTH SAN FRANCISCO, Calif. and MONTREAL,— Caprion Biosciences, a world-leading specialty contract research organization (CRO) laboratory providing state-of-the-art integrated proteomics and immune monitoring services to pharmaceutical and biotechnology clients, today announced it is offering mass cytometry services to advance biomarker discovery and immune monitoring.
“With the recent acquisition of Fremont, California-based Primity Bio Inc., we have expanded our assay development and cytometry services for preclinical and clinical research,” said Martin LeBlanc, President and CEO of Caprion. “Fluidigm mass cytometry is an advanced tool for high-content immune monitoring, providing a wealth of information from each sample. By providing high-quality mass cytometry services from custom assay design to data analysis, we further expand our offering, enabling our clients to accelerate biomarker discovery andtherapeutic development.”
Mass cytometry is an innovative application for deep immune cell profiling in translational and clinical research. Referenced by hundreds of peer-reviewed publications around the world, mass cytometry provides unique insights relative to fluorescence cytometry when high-contentanalysis is needed. With little to no signal overlap, CyTOF® allows for the simultaneous detection of over 40 parameters per cell, enabling the characterization of immune cell phenotypes, function, and signaling status in high dimension.
“Caprion Biosciences is our newest CRO mass cytometry service provider delivering multi-system capacity,” said Chris Linthwaite, President and CEO of Fluidigm. “Caprion Biosciences offers industry leading expertise, delivering new health insights in pre-clinical and
clinical research, fueled by the most powerful immune monitoring technology platform in the